Approved for use through 10/31/2002. OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Attorney Docket No. PS901 UTILITY ROSEN et al. First Inventor PATENT APPLICATION 251 Human Secreted Proteins Title TRANSMITTAL Express Mail Label No. EH853035082US (Only for new nonprovisional applications under 37 CFR ' 1.53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: Box Patent Application Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. CD-ROM or CD-R in duplicate, large table or Computer 1. Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing) Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission 2. Applicant claims small entity status. (if applicable, all necessary) See 37 CFR 1.27. Computer Readable Form (CRF) b. Specification Sequence Listing on: 3. 🔯 Specification [Total Pages 1752₁ CD-ROM or CD-R (1 copy); and (preferred arrangement set forth below) ii. paper [Total Pages 707] Descriptive title of the Invention
 Cross Reference to Related Applications Statements verifying identity of above copies c. 🖂 Statement Regarding Fed sponsored R & D
 Reference to sequence listing, a table, ACCOMPANYING APPLICATION PARTS or a computer program listing appendix Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) Assignment Papers (cover sheet and document(s)) Detailed Description - Claim(s) 10. 37 CFR 3.73(b) Statement ☐ Power of Attorney - Abstract of the Disclosure Drawing(s) (35 U.S.C. 113) [Total Sheets 4. 🔲 11. English Translation Document (if applicable) 5. 🔯 Unexecuted Declaration (Total Pages 12. Information Disclosure Statement/ Form PTO/SB/08 Copies of Citations a. Newly executed (original or copy) b. Copy from a prior application (37 CFR 1.63(d)) 13. Preliminary Amendment (for continuation/divisional with Box 17 completed) i. DELETION OF INVENTOR(S) Return Receipt Postcard (MPEP 503) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR ' ' 1.63(d)(2) and 1.33(b). (should be specifically itemized) 15. Certified copy of Priority Document(s) Application Data Sheet. See 37 CFR 1.76. (35 pages) (if foreign priority is claimed) 6. 🖂 16. Other: Serial Number Post card; and Transmittal Letter under 37 C.F.R. § 1.52. 17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76. Divisional Continuation-in-Part (CIP) of prior application No: PCT/US02/08124 Prior application information: Examiner Group/Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 18. CORRESPONDENCE ADDRESS 22195 Customer Number or Bar Code Label Correspondence address below NAME **ADDRESS** CITY STATE ZIP CODE **COUNTRY TELEPHONE** FAX NAME (Print/Type) Janet M. Martineau Registration No. (Attorney/Agent) 46,903 **SIGNATURE** Date September 20, 2003 Surden Hour Statement: this form is estimated s to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required Office U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS to complete this form should be set ADDRESS. SEND TO: Assistant C

PTO/SB/17 (01-03) Approved for use through 04/30/2003. OMB 0651-0032

	uired to	red to respond to a collection of information unless it displays a valid OMB control numb Complete if Known							
FEE TRANSMITTAL	Application Number					Not Yet Assigned			
	Filing Date			Concurrently Herewith					
for FY 2003		First Named Inventor			Rosen et al				
Patent fees are subject to annual revision.	Examiner Name				.01	Not Yet Assigned			
Applicant claims small entity status. See 37 CFR 1.27									
	Group Art Unit				-	Not Yet Assigned PS901			
	Attorney Docket No.								
METHOD OF PAYMENT (check all that apply) Check Credit Money On One	FEE CALCU				E CALCUI	LATION (continued)		
Card Order Other None	3. ADDITIONAL FEES								
X Deposit Account	Large Entity Small Entity								
Deposit Account 08-3425 Number	Fee Code	Fee (\$)	Fee Code	Fee (\$)	_	Fee Des	cription		
Deposit	1051	130	2051	65	Surcharge -	late filing fee	or oath	Fee Paid	
Account Name Human Genome Sciences, Inc.	1052	50	2052	25		-	al filing fee or cover		
The Commissioner is hereby authorized to: (check all that apply)				25	sheet.	sheet.			
Charge pay additional topic) during the pay during the			1053	130	Non-English	specification			
X Charge any additional fee(s) during the pendency of this application	1812	2,520	1812	2,520			parte reexamination		
Charge fee(s) indicated below, except for the filing fee	1804	920*	1804	920*	Requesting paction	publication of	SIR prior to Examiner		
to the above-identified deposit account.	1805	1.840*	1805	1,840*	Requesting Examiner a	publication	of SIR after		
FEE CALCULATION	FEE CALCULATION 1251 110 2251 55 Exte					or reply within	first month		
1. BASIC FILING FEE	1252	410	2252	205	Extension fo	or reply within	second month		
Large Entity Small Entity Fee Fee Fee Fee Fee	1253	930	2253	465	Extension fo	or reply within	third month		
Code (\$) Code (\$) Fee Description Fee Paid	1254	1,450	2254	725	Extension for	or reply within	fourth month		
1001 750 2001 375 Utility filing fee 750.00	1255	1,970	2255	985	Extension for reply within fifth month				
1002 330 2002 165 Design filing fee	1401	320	2401	160	Notice of Appeal				
	1402	320	2402	160		Filing a brief in support of an appeal			
1004 750 2004 375 Reissue filing fee 1005 160 2005 80 Provisional filing fee	1403 1451	280 1,510	2403 1451	140	-	Request for oral hearing			
	1452	110	2452	1,510 55	_	Petition to institute a public use proceeding Petition to revive – unavoidable			
SUBTOTAL (1) (\$) 750.00	1453	1,300	2453	650	Petition to revive - unintentional				
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,300	2501	650	Utility issue fee (or reissue)			—	
Extra Fee from Claims below Fee Paid	1502	470	2502	235	Design issue fee				
Total Claims 24 -20** = 4 x 18.00 = \$72.00	1503	630	2503	315	Plant issue fee				
Independent 4 -3** = 1 x 84.00 = \$84.00	1460	130	1460	130	Petitions to the Commissioner			-	
Claims	1807	50	1807	50	Processing fee under 37 CFR 1.17(q)				
Large Entity Small Entity	1806	180	1806	180	Submission of Information Disclosure Stmt			\vdash	
Fee Fee Fee Fee Fee Fee Peserintian	8021	40	8021	40	Poperdiag peak petant periodent				
Code (\$) Code (\$)				40	property (times number of properties) Filing a submission after final rejection			ļ	
1201 84 2201 42 Independent claims in excess of 3	1809	750	2809	375	(37 ČFR 1.129(a))				
1203 280 2203 140 Multiple dependent claim, if not paid	1810	750	2810	375	For each additional invention to be examined (37CFR 1.129(b))				
1204 84 2204 42 ** Reissue independent claims over original patent	1801	750	2801	375	Request for Continued Examination (RCE)				
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent	of a design					or expedited examination application			
	Other fee (specify)								
SUBTOTAL (2) (\$) \$156.00 *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) **or number previously paid, if greater; For Reissues, see above (S)								0.00	
SUBMITTED BY Complete (if applicable)									
Name (Prini/Type) Janet M. Martineau , Registration No. (Attorney/Agent) 46,903						Telephone (301) 315-2723			
Signature WMIXAA MILLS						Date	September 20, 2003		
	- (-)-			$\overline{}$			·		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: ROSEN et al.

Application Serial No.: to be assigned Group Art Unit: to be assigned

Filed: Concurrently herewith Examiner: to be assigned

For: 251 HUMAN SECRETED PROTEINS Attorney Docket No.: PS901

Transmittal Letter under 37 C.F.R. § 1.52

Mail Stop Sequence Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants hereby submit a CD-ROM containing the sequence listing for the above-identified application. Applicants note the following:

- 1. IBM-PC machine format;
- 2. MS-Windows operating system compatibility;
- 3. Sequence listing for PS901 (1.69 MB), created on September 18, 2003.

Applicants have also submitted a courtesy copy of the sequence listing on paper, which Applicants certify is identical to the CRF submitted herein.

Respectfully submitted,

Dated: __September 20, 2003

Janet M. Martineau (Reg. No. 46,903

Attorney for Applicants

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, MD 20850

Telephone: (301) 315-2723

KKH/JMM

RETURN RECEIPT CARD

(MPEP § 503)

OIPE:

Please Date Stamp I The B x Below And Return To Address

HUMAN GENOME Intellectual propor 9410 Key West A Rockville, MD 208

Application of: Rosen et al.

Docket No.: PS901

Application Serial No.: Not Yet Assigned

Art Unit: N/A

Filed: Concurrently Herewith

Examiner: Not Yet Assigned

Title: 251 Human Secreted Proteins

The following documents were filed by Human Genome Sciences, Inc. via Express Mail on September 20, 2003:

- 1. Return Receipt Postcard
- Serial Number Postcard to be stamped and returned
- 3. Fee Transmittal Sheet, charging \$906 to deposit account (in duplicate)
- Utility Patent Application Transmittal Letter (1 page)
- 5. Specification (1752 pps total: 24 claims-4 pp; abstract-1 page)
- 6. Unexecuted Declaration for Utility Patent Application w/ ADS (2 pages)
- 7. Application Data Sheet (35 pages)
- 8. Statement under 37 C.F.R. § 1.821 and Transmittal Letter under 37 C.F.R. § 1.52 w/ copy of Sequence Listing in paper (707 pp) and computer readable form (1 copy of CDR 665k).

KKH/JMM

Express Mail Label No. EH853035082US Dated: September 20, 2003